MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » FDA approves trial for low-risk patients with MDT’s CoreValve Evolut R

FDA approves trial for low-risk patients with MDT’s CoreValve Evolut R

By

Medtronic's CoreValve Evolut R TAVRMedtronic (NYSE:MDT) said today that the FDA granted an investigational device exemption for a clinical trial of its CoreValve Evolut R implantable heart valve in patients at low risk for adverse events from traditional heart valve replacement surgery.

The expanded indication means a likely spring debut for the 1,200-patient trial in patients with severe aortic stenosis with a less than 3% chance of dying with surgical valve replacement. The CoreValve Evolut R is a transcatheter aortic valve implant that’s already been approved in the U.S. for high- and extreme-risk patient cohorts.

The primary endpoint for the trial is slated to be all-cause mortality or disabling stroke at 2 years, but includes a provision for a 1-year analysis for early submission to the FDA, Fridley, Minn.-based Medtronic said. The study is also designed to evaluate a sub-group of 400 patients for leaflet mobility, a complication associated with the risk for blood clots that prompted an FDA warning late last year.

Enrollment in the trial is due to begin this spring, the company said.

“Medtronic is committed to expanding access to [transcatheter aortic valve replacement] for patients who may benefit based on a robust clinical evidence portfolio,” heart valve therapies general manager Rhonda Robb said in prepared remarks. “We are excited to partner with such proven heart teams to study the CoreValve Evolut R self-expanding platform in this low risk patient population.”

“This trial comes on the heels of data showing patients who underwent TAVR with this self-expanding platform demonstrated superior survival benefit -with low and stable stroke rates- compared to SAVR patients,” added principal investigator Dr. Michael Reardon of the Houston Methodist DeBakey Heart & Vascular Center. “This study is an important next step in developing robust clinical evidence to help heart teams understand the potential benefits of TAVR in a broader patient population.”

Earlier this month, the FDA granted an expanded indication for the CoreValve devices for patients with end-stage renal disease and low-grade, low-flow aortic stenosis.

In case you missed it

RSS From Medical Design & Outsourcing

  • Integra plans to shrink the C-suite after executive’s exit
    Integra Lifesciences (Nasdaq: IART) will eliminate the position of chief operating officer next week — though the office is already empty. Former COO Glenn Coleman’s last day at Integra was Friday, according to a separation agreement filed with the Securities and Exchange Commission that same day. Coleman was scheduled to start as the new EVP and… […]
  • Steris plans to build a new medical device testing facility
    Steris (NYSE: STE) plans to build a new packaging and microbiological testing facility for medical devices in Leipzig, Germany. The facility will offer packaging testing services such as accelerated and real-time aging, transportation and integrity testing. The new location will also offer microbiological testing in collaboration with the medical device manufacturer and sterilizer’s laboratory in… […]
  • 10 medical device startups you need to know
    Some of the most interesting medical device startups of 2022 are advancing a wide range of innovative medtech: robotics, catheter-delivered brain-computer interfaces and more. The editors here at Medical Design & Outsourcing and MassDevice are writing about medical device startups all the time. But there are some device companies starting out that have technologies that… […]
  • Steris stock downgraded as analysts expect lawyers to seek more ethylene oxide lawsuits
    Steris (NYSE: STE) stock was downgraded today by Needham from buy to hold following the $363 million jury verdict against its primary competitor, Sterigenics, over ethylene oxide (EtO) emissions. Needham analysts said they expect attorneys to target communities near EtO facilities with ads to find people willing to file more lawsuits against sterilization plant operators… […]
  • Researchers develop at-home device to track Parkinson’s progression
    Researchers at MIT and the University of Rochester Medical Center have developed a device to monitor a Parkinson’s patient at home. Collecting data at home could help provide a less subjective measurement than evaluations at the doctor’s office, which can be affected by outside factors. The technology could also help pharmaceutical and biotech companies developing… […]
  • Micro Mold renovates for new 5-axis milling center
    Precision mold maker Micro Mold has renovated in Erie, Pennsylvania, to make room for its new Yasda YMC650 high-speed 5-axis milling center and 3R Workpartner automation cell. The new equipment will be used for electrode manufacturing and finishing hard mill applications. The milling machine is accurate to 1 micron for high-volume, ultra-precision tooling work, the… […]
  • September 2022 Issue: The Medtech Big 100 is bigger than ever
    Medtech sales reach a record high as R&D spend and employee counts climb Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future Autotransfusion device maker ships units to Ukraine How IP protection is enabling robotic surgery innovation Connected device design for the real world: Managing the development process FDA details plans to expand… […]
  • How NeuroOne and Zimmer Biomet will partner on robotic brain surgery
    NeuroOne (NASDAQ: NMTC) is preparing its depth electrode technology for commercialization through Zimmer Biomet (NYSE: ZBH) while waiting for FDA feedback on its latest submission. NeuroOne’s Evo stereoelectroencephalography (sEEG) device won FDA 510(k) clearance in September 2021 for recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. That clearance was… […]
  • Trelleborg to show off advanced polymer tech at MD&M Minneapolis
    Trelleborg Healthcare & Medical will exhibit advanced polymer technologies for medical applications at MD&M Minneapolis, which runs Nov. 2–3, 2022. The Sweden-based engineering polymer giant, which has operations in 50 companies, has newly acquired, advanced capabilities in thermoplastic injection molding. The new injection molding capabilities come from its purchase of Menomonie, Wisconsin–based EirMed earlier this… […]
  • Millstone Medical Outsourcing expands cleanroom facility
    Millstone Medical Outsourcing said today that it has broken ground on a 5,000-square-foot cleanroom facility expansion at its Fall River, Massachusetts headquarters. The project is Millstone’s third cleanroom expansion. The additional Class 10,000/ISO7-rated cleanroom space is for medical device packaging operations. It will bring the company’s total cleanroom footprint to 20,000 square feet. Responding to… […]
  • Johnson & Johnson launches Bay Area science and technology campus
    Johnson & Johnson (NYSE:JNJ) has opened an almost 200,000 ft2 science and technology campus in the San Francisco Bay Area. The new facility more than doubles the presence of the company in the Bay Area, which has been a hub for life sciences innovation for decades. Up to 400 employees will work at the facility. “This… […]